Taiwan Liposome Company Ltd ADR (TLC) Fundamental Analysis & Valuation

NASDAQ:TLC

Current stock price

7
0 (0%)
Last:

This TLC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

No Fundamental Analysis report for TLC not available.

TLC Fundamentals: All Metrics, Ratios and Statistics

Taiwan Liposome Company Ltd ADR

NASDAQ:TLC (9/28/2021, 8:00:01 PM)

7

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)10-27
Earnings (Next)01-11
Inst Owners0.22%
Inst Owner Change1.48%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap294.54M
Revenue(TTM)9.91M
Net Income(TTM)-28.93M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.72
P/FCF N/A
P/OCF N/A
P/B 14.8
P/tB N/A
EV/EBITDA -9.96
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.24
BVpS0.47
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.71%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -306.57%
PM (TTM) -291.85%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.01
Quick Ratio 3.01
Altman-Z 1.92
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.91%
EPS Next Y4.76%
EPS Next 2Y-4.91%
EPS Next 3Y-1.02%
EPS Next 5Y-0.76%
Revenue 1Y (TTM)397.16%
Revenue growth 3Y29.41%
Revenue growth 5YN/A
Sales Q2Q%1353.56%
Revenue Next Year-35.08%
Revenue Next 2Y0.24%
Revenue Next 3Y2.83%
Revenue Next 5Y4.54%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Taiwan Liposome Company Ltd ADR / TLC Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for Taiwan Liposome Company Ltd ADR?

ChartMill assigns a fundamental rating of 2 / 10 to TLC.


What is the valuation status for TLC stock?

ChartMill assigns a valuation rating of 0 / 10 to Taiwan Liposome Company Ltd ADR (TLC). This can be considered as Overvalued.


What is the profitability of TLC stock?

Taiwan Liposome Company Ltd ADR (TLC) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for TLC stock?

The Earnings per Share (EPS) of Taiwan Liposome Company Ltd ADR (TLC) is expected to grow by 4.76% in the next year.